MedPath

Acute aspirin plus cilostazol Dual Therapy for non-cardioembolic stroke patients within 48 h of symptom onset -a prospective, multicenter, randomized, an aspirin-controlled study

Not Applicable
Recruiting
Conditions
on cardioembolic stroke
Registration Number
JPRN-UMIN000004950
Lead Sponsor
Stroke Medicine Kawasaki Medical School
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
2000
Inclusion Criteria

Not provided

Exclusion Criteria

cardioembolic stroke preadmission antithrombotic therapy (cilostazol, aspirin 200mg or over, clopidgrel, ticlopidine, anticoagulants) congestive heart failure pregnancy allergy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
modified Rakin scale score at 3 months after stroke neurological worsening within 14 days of stroke onset TIA, stroke reccurence, intracerebral hemorrhage, subarachnoid hemorrhage within 14 days of stroke onset
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath